Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1479-5876
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis ; volume:10 ; number:3 ; day:28 ; month:11 ; year:2012 ; pages:1-2 ; date:11.2012
Journal of translational medicine ; 10, Heft 3 (28.11.2012), 1-2, 11.2012

Urheber
Martínez-Pérez, Rosalia
Beteiligte Personen und Organisationen
Rodríguez-Montero, Sergio
Muñoz, Alejandro
Uceda, Julia
León, Mario
Gallo, Francisco
Velloso, Maria Luisa
Marenco, Jose Luis
SpringerLink (Online service)

DOI
10.1186/1479-5876-10-S3-P51
URN
urn:nbn:de:1111-2016041443468
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:58 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Martínez-Pérez, Rosalia
  • Rodríguez-Montero, Sergio
  • Muñoz, Alejandro
  • Uceda, Julia
  • León, Mario
  • Gallo, Francisco
  • Velloso, Maria Luisa
  • Marenco, Jose Luis
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis

Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis

Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab

Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab

Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment

Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment

Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept

Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept

Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study

Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study

Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany

Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany

Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis

Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis

Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis

Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis

Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis

Etanercept und Adalimumab: wirksam und sicher bei Kleinkindern mit JIA

Etanercept und Adalimumab: wirksam und sicher bei Kleinkindern mit JIA

Verbundene Objekte